Daily Bulletin

CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision

HONG KONG, July 13, 2021 /PRNewswire/ -- Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia. AK117 resulted in no dose-limiting toxicity (DLT) and no anemia of clinical...

Read more: CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to...

Business News

Tips from Organisational Change Management Experts for Leading Successful Transitions

Corporate evolution has accelerated dramatically in today's volatile business environment, requiring leaders to develop sophisticated approaches to managing workforce transitions across technologica...

Daily Bulletin - avatar Daily Bulletin

Cross-Continental Collaboration: Nutifood and Viplus Dairy to Create Australian- Standard Premium Dairy Brand

Vietnam’s Nutifood has officially entered a strategic partnership with ViPlus Dairy, a heritage-rich dairy manufacturer with over 130 years of experience in Gippsland, Australia, to establish an int...

Daily Bulletin - avatar Daily Bulletin

Beyond the Marker: How Modern Whiteboards Drive Team Collaboration

In an age where flexibility and innovation define competitive advantage, the humble whiteboard has undergone a transformation. From static office fixture to dynamic collaboration hub, modern whiteboar...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals